ACAD: 阿卡迪亚

ACAD新闻

• 17:26 Tracking Baker Brothers Portfolio: Q1 2026 Update
• 14:47 Acadia Gets FDA's Fast Track Tag for Alzheimer's Disease Candidate
• 06:15 Stoke Therapeutics: Its Dravet Syndrome Lead Asset Enters The Last Stretch (NASDAQ:STOK)
• 16:40 Markets Heading Toward The Cone Of Uncertainty
• 09:45 Verastem (VSTM) Surges 6.3%: Is This an Indication of Further Gains?
• 15:40 RPRX or ACAD: Which Is the Better Value Stock Right Now?
• 17:08 About That 'Robust' Earnings Growth
• 15:19 Acadia Pharmaceuticals: Steady Commercial Progress, Remlifanserin Data In Focus
• 15:15 ACAD Stock Up as CHMP Backs Daybu for EU Approval in Rett Syndrome
• 13:37 Strength Seen in Acadia (ACAD): Can Its 6.8% Jump Turn into More Strength?
• 20:33 Stock Indexes Finish Lower as Chipmakers Sell Off
• 14:24 The Surprising Reversal That Drove Acadia Pharma Closer To A Breakout
• 15:30 Acadia (ACAD) Down 3.7% Since Last Earnings Report: Can It Rebound?